PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.
A user shared a 4-month hair loss progress update using a daily pill containing 1.1mg finasteride, 3mg minoxidil, and biotin, along with weekly Ketoconazole shampoo. They noted significant improvement and advised against using expensive teledoc services.
The user reports positive results from using 0.5 mg dutasteride daily for four months and 2.5 mg oral minoxidil for three months, with no side effects. They switched from topical minoxidil to this oral combination.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A user shared their 4-year progress using finasteride (1 mg) and 11 months of oral minoxidil (2.5 mg) for hair loss. They reported thicker, better-quality hair with no side effects and plan to continue the regimen, possibly adding micro-needling and dutasteride.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
A user's progress with treating hair loss, using minoxidil, finasteride and microneedling. The user experienced impressive results after four months of treatment, and mentioned that stopping recreational drugs and losing weight helped their hair regrowth.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
This user, "ediblediety", has been taking oral minoxidil (1.25 mg daily), keto shampoo and occasional derm-rolling for 4 months to treat their hair loss, and they have experienced a shedding phase after the first few weeks of use. They report improvements in the thickness of their facial and body hair, but note that this may be daunting to women.
The user experienced significant hair regrowth over four months using oral finasteride, oral minoxidil, micro-needling, and rosemary oil. They reported no side effects and emphasized the importance of continuing the treatment to maintain results.
PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
The user shared their 4.5-month progress using oral finasteride, topical minoxidil, and oral dutasteride, along with biotin, vitamin D, saw palmetto, and multivitamins. They use a combination of finasteride and dutasteride weekly, with micro-stamping, to address hair loss.
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.
The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.
The conversation discusses hair loss treatments, specifically oral minoxidil (2.5mg), dutasteride (0.5mg every other day), and ketoconazole. The user reports slow progress but significant hair growth after adding ketoconazole to their routine.
A user's progress with a hair loss treatment regimen consisting of minoxidil, finasteride, and dermarolling once a week over four months; other users have offered encouragement and advice.
Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.
A 23-year-old male used 1.25mg finasteride every other day for 10 months without minoxidil, noticing results at the 4-month mark and experiencing a minor shed at the 8-month mark. He also added Nizoral to his routine and reported no side effects, maintaining consistent use at 7:00 PM.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
A user shared their 4-year experience with oral finasteride and 2-year experience with oral minoxidil for hair regrowth, noting minor side effects like weaker erections and increased hair growth elsewhere. They reported significant regrowth primarily from finasteride and maintained a consistent dosage of 1mg finasteride and 2.5mg minoxidil daily.
The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.
The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.